2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2935 Infection prevention practices for children with sickle cell disease: A survey of pediatric sickle cell disease providers

Kevin Nabih Marzotto, MD, Joshua Raymond Tanzer, PhD2, Patrick T. McGann, MD3, Manpreet Kochhar, MD4
1 Brown University School of Medicine, Providence, Rhode Island, United States
2 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
3 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
4 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States

Background: Children with sickle cell disease (SCD) are at significant risk of life-threatening bacterial infections due to functional asplenia. Following publication of the PROPS trial in 1986, prophylactic penicillin (PCN) through 5 years of age as the standard for children with SCD has led to significant reduction in the incidence of invasive bacterial infections and infection-associated mortality. Notably, both PROPS and PROPS II enrolled only children with the more severe SCD genotypes (HbSS and HbS/b0-thalassemia (thal)), but many clinical practitioners provide PCN prophylaxis for all SCD genotypes due to lack of evidence and the desire to prioritize patient safety. Current national guidelines conflict with the 2014 NHLBI guidelines recommending prophylactic PCN only in HbSS and the 2025 National Alliance of Sickle Cell Centers (NASCC) Consensus statement recommending PCN in all SCD genotypes. This study aims to describe this practice variation as it relates to SCD genotype, provider demographics, and other patient- and provider-specific factors with the goal of identifying opportunities for practice harmonization among pediatric SCD providers.

Design/Methods: A cross-sectional, electronic survey-based study of pediatric SCD providers in the United States and Canada was conducted from 1/28/2026 to 5/26/2026. The survey assessed six domains: provider demographics, PCN prophylaxis prescribing practices, vaccination practices, miscellaneous clinical practices, factors influencing PCN adherence, and responses to clinical scenarios. Participants were invited via email and through the American Society of Pediatric Hematology/Oncology (ASPHO) online community. Data were stored on Brown University Health REDCap. The IRB determined that the study met the criteria for exemption after full IRB review. Data was analyzed using R.

Results: Among the 75 participants, 62 surveys were fully completed and included in the study analysis. The respondents consist of 52 MD/DO attendings, 5 Advanced Practice Providers, and 5 trainees, with a mean of 12.8 ± 8.6 years of clinical experience and geographic representation from the Northeast (45%), Southeast (24%), Midwest (18%), West (5%), Southwest (5%), and Canada (3%). Cluster analysis identified two distinct groups. Group 1 (had significantly fewer years of clinical experience (7.9 [5.9–10.3] vs 15.4 [13.4–18.1]) and cared for more patients with SCD (460.5 [388.3–522.9] vs 251.3 [197.7–303.7]) than group 2. Overall, 66% of providers reported prescribing PCN to all genotypes. Among providers who did not routinely prescribe to all genotypes (34%), PCN was prescribed for HbSS (100%), HbS/β°-thal (95%), HbSC (76%), HbS/β?-thal (67%), HbSD (29%), HbS-O-Arab (24%), and HbSE (14%). Group 1 was statistically more likely to prescribe PCN to patients with HbS/β°-thal (89% [77–100] vs 54% [36–69]) and HbS-O-Arab (74% [56–88] vs 41% [26–55]) than group 2. Across all genotypes, 81–85% of providers discontinued PCN at age 5, 5% continued indefinitely, and 6–10% used shared decision-making. Following a prior invasive infection, providers more commonly recommended indefinite PCN for higher risk genotypes (66%), whereas a defined duration was recommended far less frequently (16%). In contrast, for less severe genotypes, providers less commonly recommended indefinite PCN (54%) and preferred a defined duration (25%). Similar trends were observed following surgical splenectomy, with indefinite PCN favored in higher risk genotypes (61% vs 57%) and extension of prophylaxis for 1–3 years favored for less severe genotypes (25% vs 23%).

Conclusions: This study demonstrates that substantial variation in prophylactic PCN practices persists among pediatric SCD providers. Although the 2025 NASCC guidelines recommend prophylaxis for all SCD genotypes, 35% of surveyed providers reported not prescribing to all genotypes. Providers with less clinical experience and those practicing at higher-volume SCD centers were significantly less likely to prescribe PCN for children with HbS/β°-thal and HbS-O-Arab. The study findings suggest no clear consensus currently exists regarding prophylactic PCN prescribing practices. These findings likely reflect persistent evidence gaps, advances in vaccines, and ever-changing consensus recommendations. Defining current practice patterns may help inform clinical decision-making, identify areas of uncertainty, and guide future consensus development.

Kevin Nabih Marzotto, MD: No relevant conflicts of interest to declare.